Deals & Financings - ChinaBio® Today

Recent Articles

Changchun BCHT Biotech Acquires Flu Vaccine Technology Feb 10, 2012: Changchun BCHT Biotechnology obtained an exclusive license for a live attenuated influenza (LIAV) vaccine technology from BioDiem, an Australian vaccine company. The license gives BCHT exclusive China rights to the technology for an egg-based production method in pandemic and seasonal influenza vaccines. Although the license is limited to LAIV for private market vaccines, BCHT holds a second license to LAIV for China’s public market in China via a sub-license from the World Health Organization. More details....

Share this with colleagues:

Shanghai Pharma to Spend $80 Million on North China Expansion Feb 9, 2012: Shanghai Pharmaceuticals announced a plan to set up a Beijing headquarters for North China. The company will establish a new entity, which will be called Shanghai Pharma Northern Investment Co., Ltd. and capitalized with $80 million. According to the company, Shanghai Pharma Northern will coordinate the company’s various subsidiaries in the region and take responsibility for further investment in North China. More details....

Stock Symbol: (SHA: 601607; HKEX: 02607)

Share this with colleagues:

Once Again, Fosun Pharma Plans Hong Kong IPO Feb 8, 2012: Shanghai Fosun Pharma's on-again/off-again Hong Kong IPO is apparently now scheduled to take place early this year. According to an unnamed insider, the company has filed its listing application with the Hong Kong exchange. Fosun hopes to raise between $600 million and $800 million by floating up to a 20% stake in the company. More details....

Stock Symbol: (SHA: 600196)

Share this with colleagues:

Shanghai Biochip Signs MOU with GeneNews of Canada Feb 7, 2012: Shanghai Biochip, also known as ShanghaiBio Corp.,signed an MOU with GeneNews Limited, a Canadian molecular diagnostics company. The agreement calls for GeneNews and SBC to set up a Sentinel Center for Personalized Medicine in China, based on GeneNews’ Sentinel technology. The Center will seek to co-develop and commercialize molecular diagnostic products. Also, SBC will gain non-exclusive rights to market and sell GeneNews' ColonSentry™ test in China. More details....

Share this with colleagues:

Nanjing Pharma’s Weak Financials Spark Takeover Talk Feb 7, 2012: Nanjing Pharmaceutical, a company that makes and distributes pharmaceuticals, announced it will report a loss for 2011. The company blamed the loss on higher interest payments on its $387 million of debt. Nanjing Pharma is the largest drug distributor in China’s eastern provinces of Jiangsu, Anhui and Fujian. The combination of lower valuation and leading market position sparked speculation that one of China’s major drug distribution companies will make a bid for Nanjing Pharma. More details....

Stock Symbol: (SHA: 600713)

Share this with colleagues:

Shanghai Pharma Acquires Second API Maker this Year Feb 6, 2012: Shanghai Pharmaceuticals will buy Changzhou Kony Pharm Co., a company that makes APIs for antivirals and cardiovascular drugs. Shanghai Pharma positioned the acquisition as mutually advantageous. It is also a way for Shanghai Pharma to put some of the $2 billion garnered from its Hong Kong IPO to work. Although the price was not disclosed, Kony Pharma was estimated to be worth about 300 million RMB ($47.6 million). . In January, Shanghai Pharma purchased a 51% share in Jinhe Bio-Technology, a company that specializes in APIs for cancer drugs. More details....

Stocik Symbol: (SHA: 601607; HK: 02607)

Share this with colleagues:

Cardinal Health Plans $90 Million in China Acquisitions Feb 3, 2012: Cardinal Health, the US-based drug distributor, plans to make $90 million in China acquisitions to bolster its geographic coverage in mainland China. In addition, Cardinal said it is expanding its China product offerings to include medical products, lab equipment and other supplies. Earlier, Cardinal had announced a plan to make acquisitions, but it now seems to have made deals, though it hasn't released any specifics. More details....

Stock Symbol: (NYSE: CAH)

Share this with colleagues:

Tasly and SemBioSys Report Progress on their China JV Feb 2, 2012: Tianjin Tasly Pharma and SemBioSys Genetics of Canada have received business licenses for their Tianjin-based JV, which is based on SemBioSys’ seed-based oilbody and genetic expression technology. Ultimately, the JV expects to use the technology to produce insulin for China and the rest of world. In the near-term, it will develop modernized TCM products and nutraceuticals. After that, the JV will turn its focus toward animal food additives. More details....

Stock Symbols: (SHA: 600535) (TSX: SBS)

Share this with colleagues:

WuXi PharmaTech and ShangPharma Are M&A Targets: Bloomberg Feb 1, 2012: WuXi PharmaTech and ShangPharma are both attractive M&A targets, according to a Bloomberg News article. Both China CROs have higher profit margins than their US peers, and both are growing faster than US CROs. Nevertheless, their PE ratios are lower, making them value propositions for their US competitors. To gain perspective on the situation, Bloomberg quoted Greg Scott, ChinaBio®’s CEO, who said China’s CRO industry is healthy, with demand growing steadily. Both companies have the “ability to deliver a cost advantage while maintaining very high quality,” he added. More details....

Stock Symbol: (NYSE: WX) (NYSE: SHP)

Share this with colleagues:

EntreMed Raises $10 Million from China-Connected Investors Jan 23, 2012: EntreMed, a clinical stage US biotech, landed $10 million from a group of investors with China roots. The investors included Tak W. Mak, PhD, a renowned cancer scientist who discovered EntreMed’s leading drug candidate, ENMD-2076. Dr. Mak is a previous investor in EntreMed and is also a part of a company that owns the China rights to ENMD-2076. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues: